IDO1 and bladder transitional cell carcinoma: Since IDO‐1 acts as a potent T‐cell inhibitor through metabolic restrictions [114], restoring its levels by pharmacologically targeting COX‐2 activity improves antitumor response and ICI efficacy in animal models of urothelial bladder carcinoma [113].